Back to mobile site

Oppenheimer on Gilead Sciences (GILD): 'Story Near-Term Remains Squarely HIV Focused'

April 8, 2026 6:01 AM EDT Send to a Friend
Oppenheimer analyst Hartaj Singh reiterated an Outperform rating and $165.00 price target on Gilead Sciences (NASDAQ: GILD).The analyst comments "Gilead's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login